News | Radiology Business | June 27, 2019

Blue Earth Diagnostics to be Acquired by Bracco Imaging

Blue Earth Diagnostics to become a subsidiary of Bracco Imaging; retains name and management team

Blue Earth Diagnostics, a molecular imaging diagnostics company, announced that a definitive agreement has been signed for Bracco Imaging S.p.A. to acquire all outstanding shares of privately-held Blue Earth Diagnostics from leading healthcare company Syncona for $450 million plus closing adjustment estimated at $25 million. Upon closing of the transaction, Blue Earth Diagnostics will be a subsidiary of Bracco Imaging, led by its current leadership team and will retain the well-established Blue Earth Diagnostics name. Bracco Imaging is a leader in the diagnostic imaging business with an integrated product offering from a diverse roster of subsidiary companies.

“The acquisition of Blue Earth Diagnostics by Bracco Imaging is a validation of the quality of our people, our pipeline of novel diagnostic agents such as rhPSMA and the proven success of Axumin for imaging in prostate cancer and potentially other future indications,” said Jonathan Allis, D.Phil., chief executive officer, Blue Earth Diagnostics. “We believe this acquisition is excellent for Blue Earth as Bracco Imaging’s global footprint and clinical research and marketing support will enable us to expand the reach of our high-value platform of innovative radiopharmaceuticals to inform clinical management and guide care for even more people with cancer around the world.”

Blue Earth Diagnostics’ first commercialized product, Axumin (fluciclovine F 18) injection is a novel molecular imaging agent approved in the United States and the European Union for use in PET imaging for men with suspected recurrent prostate cancer. Axumin is widely available and used across the United States, with more than 50,000 doses administered to date. 18F-Fluciclovine has a broad range of other potential applications in cancer imaging and Blue Earth Diagnostics is investigating the molecule for utility in other cancers, including in neuro-oncology.

In April 2018, Blue Earth Diagnostics expanded its prostate cancer portfolio through the acquisition of exclusive, worldwide rights to a broad family of Prostate Specific Membrane Antigen (PSMA)-targeted radiohybrid (“rh”) agents for cancer. rhPSMA is a clinical-stage, investigational class of theranostic compounds, with potential applications in both the imaging and treatment of prostate cancer.

“Blue Earth Diagnostics’ innovative products and pipeline will significantly enhance Bracco Imaging’s portfolio in precision medicine and personalized diagnostics, while expanding our range of nuclear oncology imaging solutions in the Urology segment and other specialties,” said Fulvio Renoldi Bracco, Chief Executive Officer, Bracco Imaging. “We are thrilled to welcome to Bracco this world class team with exceptional product development and commercialization expertise.”

“We are so proud of our exceptional, patient-focused team for building a successful radiopharmaceuticals business in only five years. This acquisition provides us the tremendous opportunity to grow and expand Axumin, and our innovative pipeline, geographically and into other therapeutic targets,” added Allis. “We also wish to acknowledge Syncona for its role in the foundation of the company, and its operational and financial acumen as we have built the business.”

For more information: www.braccoimaging.com

Related Content

Image by rawpixel from Pixabay

Image by rawpixel from Pixabay 

Feature | Radiology Business | July 18, 2019 | By Stefanie Manack and Judy Zakutny
Approximately 30 percent of a hospital or health system’s profit comes from imaging according, to...
CMS Proposes New Alternative Payment Model for Radiation Oncology
News | Radiation Oncology | July 17, 2019
The Centers for Medicare and Medicaid Services (CMS) issued a proposal for an advanced alternative payment model (APM)...
Routine scan of abdomen pelvis taken with the UW-Madison’s Revolution 256 CT scanner using the FDA-cleared reconstruction algorithm, called TrueFidelity.

Routine scan of abdomen pelvis taken with the UW-Madison’s Revolution 256 CT scanner using the FDA-cleared reconstruction algorithm, called TrueFidelity. UW-Madison was the first site in the U.S. to get this technology. Its use is now being integrated into UW CT protocols. Image courtesy of Timothy P. Szczykutowicz

Feature | Computed Tomography (CT) | July 12, 2019 | By Greg Freiherr
When providers develop their own imaging protocols, they are wasting time and money, according to...

Image courtesy of GE Healthcare

Feature | Radiology Business | July 03, 2019 | By Jeffrey Hoffmeister, M.D.
Burnout in the medical profession is not uncommon, particularly as clinicians have become more overwhelmed by growing

stock.adobe.com / netsign

Feature | Radiology Business | July 02, 2019 | By William W. Pinsky, M.D., FAAP, FACC, and Mandeep R. Mehra, M.D., MBBS, MSc, FRCP
As we strive to process today’s successive news cycles involving negative reports about immigration, it is easy for m
The Current Direction of Healthcare Reform Explained by CMS Administrator Seema Verma
News | Radiology Business | June 11, 2019
June 11, 2019 — Centers for Medicare and Medicaid Services (CMS) Administrator Seema Verma addressed the American Med
ASTRO Applauds New Prior Authorization Legislation
News | Radiation Therapy | June 07, 2019
The American Society for Radiation Oncology (ASTRO) released a statement applauding Congress’s introduction of...
Applications Open for ASRT Foundation and Canon Medical's Safety FiRsT Grant Program
News | Radiation Dose Management | May 31, 2019
The ASRT Foundation and Canon Medical Systems are now accepting applications for the 2019 Safety FiRsT grant program,...